비소세포 폐암환자에서 Real-time PCR을 이용한 혈장 Heterogeneous Ribonucleoprotein B1 mRNA 상대정량의 유용성 = Comparative Quantification of Plasma hnRNP B1 mRNA in Non-small Cell Lung Cancer Patients by Real-time PCR

다국어 초록 (Multilingual Abstract)

Background : Circulating cell-free nucleic acids are known to be a noninvasive diagnostic tool for cancer detection. Heterogeneous nuclear ribonucleoprotein (hnRNP) B1, a nuclear core complex, is overexpressed in early stage lung cancer. We intended to evaluate the usefulness of plasma hn-RNP B1 mRNA in differentiating non-small cell lung cancer (NSCLC) from other benign lung diseases, especially pulmonary tuberculosis, which is highly prevalent in Korea and often difficult to distinguish from lung cancer.
Methods : Plasma RNA was extracted from 30 patients with NSCLC, 30 patients with benign lung diseases including pulmonary tuberculosis, and 10 healthy controls. Plasma hnRNP B1 mRNA was measured by TaqMan Gene Expression Assay (Applied Biosystems, USA), and pre-developed betaactin
(ACTB) mRNA was used for normalization. We analyzed the relative gene expression data using the delta-delta Ct method.
Results : Plasma hnRPN B1 mRNA was measurable in 93.3% (28/30) of NSCLC patients. Normalized 2-ΔΔCt of plasma hnRPN B1 mRNA was 62.2 (95%Cl, 6.4-210.1) in NSCLC patients and 2.7 (95% Cl, 0.5-13.6) in benign lung disease patients (P<0.001, Mann-Whitney U test).
Conclusions : Plasma hnRNP B1 mRNA was significantly increased in patients with lung cancer compared with that in patients with other benign lung diseases. Plasma hnRNP B1 mRNA may be useful as a potential marker for the detection of NSCLC.

국문 초록 (Abstract)

배경 : 혈장에서 검출되는 핵산(cell-free nucleic acids)이
최근 암의 진단에 있어 비침습적 표지자로 유용한 것으로 알려져 있다. Nuclear core complex의 하나인, heterogeneous
nuclear ribonucleoprotein (hnRNP) B1은 폐암 초기에 과발
현 되는 것으로 알려져 있다. 본 연구에서는 한국에서 유병률이
높고, 종종 폐암과 구별이 어려운 폐결핵을 포함한 양성폐질환
으로부터 비소세포 폐암환자를 확인하는데 혈장 hnRNP B1
mRNA가 유용한지 알아보고자 하였다
방법 : 비소세포 폐암환자 30명, 폐결핵을 포함한 양성 폐질
환자 30명, 정상인 10명을 대상으로 혈장에서 RNA를 추출하였
다. 혈장hnRNP B1 mRNA를 측정하기 위해 predesigned, validated
TaqMan Gene Expression Assay (Applied Biosystems,
USA)를 이용하였고, 상대적인 정량을 위해 pre-developed
beta-actin (ACTB) mRNA을 사용하였다. Delta-delta
Ct 방법을 이용하여 상대적으로 정량하였다.
결과 : 비소세포 폐암환자 93.3% (28/30)에서 혈장 hnRNP
B1 mRNA가 측정되었다. 정상인의 hnRNP B1 mRNA로 보정
한 상대 발현 값인 2-ΔΔCt는 비소세포 폐암환자군에서 62.2 (95%
신뢰구간; 6.4-210.1), 양성폐질환자군에서 2.7 (95% 신뢰구간;
0.5-13.6)로 통계적으로 유의하게 높게 발현되었다(P<0.001,
Mann-Whitney U test).
결론 : 혈장 hnRNP B1 mRNA는 정상대조군 또는 양성폐질
환군에 비해 비소세포 폐암환자에서 유의하게 증가되어 있었다.
따라서, 혈장 hnRNP B1 mRNA는 암표지자로서 비소세포성
폐암의 검출에 유용할 수 있을 것으로 판단된다.

참고문헌 (Reference)

1 Wu S, "hnRNP B1 protein may be a possible prognostic factor in squamous cell carcinoma of the lung" 41 : 179-186, 2003

2 Zhou J, "a protein that permits early detection of lung cancer. Identification of heterogeneous nuclear ribonucleoprotein-A2/B1 as the antigen for monoclonal antibody 703D4" 271 : 10760-10766, 1996

3 Sozzi G, "Quantification of free circulating DNA as a diagnostic marker in lung cancer" 21 : 3902-3908, 2003

4 Zech VF, "Prognostic and diagnostic relevance of hnRNP A2/B1, hnRNP B1 and S100 A2 in non-small cell lung cancer" 30 : 395-402, 2006

5 Beau-Faller M, "Plasma DNA microsatellite panel as sensitive and tumor-specific marker in lung cancer patients" 105 : 361-370, 2003

6 Chen XQ, "Microsatellite alterations in plasma DNA of small cell lung cancer patients" 2 : 1033-1035, 1996

7 Melamed MR, "Lung cancer screening results in the National Cancer Institute New York study" 89 : 2356-2362, 2000

8 Matsuyama S, "Heterogeneous nuclear ribonucleoprotein B1 expressed in esophageal squamous cell carcinomas as a new biomarker for diagnosis" 91 : 658-663, 2000

9 Sueoka E, "Heterogeneous nuclear ribonucleoprotein B1 as early cancer biomarker for occult cancer of human lungs and bronchial dysplasia" 61 : 1896-1902, 2001

10 Mayeda A, "Function of conserved domains of hnRNP A1 and other hnRNP A/B proteins" 13 : 5483-5495, 1994

11 Leon SA, "Free DNA in the serum of cancer patients and the effect of therapy" 37 : 646-650, 1977

12 Sato A, "Establishment of a new method, transcription-reverse transcription concerted reaction, for detection of plasma hnRNP B1 mRNA, a biomarker of lung cancer" 134 : 1191-1197, 2008

13 Kopreski MS, "Detection of tumor messenger RNA in the serum of patients with malignant melanoma" 5 : 1961-1965, 1999

14 Sueoka E, "Detection of plasma hnRNP B1 mRNA, a new cancer biomarker, in lung cancer patients by quantitative real-time polymerase chain reaction" 48 : 77-83, 2005

15 Bruhn N, "Detection of microsatellite alterations in the DNA isolated from tumor cells and from plasma DNA of patients with lung cancer" 906 : 72-82, 2000

16 Fleischhacker M, "Detection of amplifiable messenger RNA in the serum of patients with lung cancer" 945 : 179-188, 2001

17 Esteller M, "Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients" 59 : 67-70, 1999

18 Andriani F, "Detecting lung cancer in plasma with the use of multiple genetic markers" 108 : 91-96, 2004

19 Livak KJ, "Comparative Ct Method. ABI PRISM 7700 Sequence Detection System. User Bulletin No. 2. Relative Quantitation of Gene Expression. PE Applied Biosystems"

20 Bremnes RM, "Circulating tumour-derived DNA and RNA markers in blood: a tool for early detection, diagnostics, and follow-up?" 49 : 1-12, 2005

21 Jemal A, "Cancer statistics, 2007" 57 : 43-66, 2007

22 National Cancer Information Center, "Cancer incidence"

23 Livak KJ, "Analysis of relative gene expression data using real-time quantitative PCR and the 2 (-Delta Delta C[T]) Method" 25 : 402-408, 2001

24 Sozzi G, "Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients" 61 : 4675-4678, 2001

25 Soria JC, "Aberrant promoter methylation of multiple genes in bronchial brush samples from former cigarette smokers" 62 : 351-355, 2002

26 Mulcahy HE, "A prospective study of K-ras mutations in the plasma of pancreatic cancer patients" 4 : 271-275, 1998